Stock Information

• Roivant’s Immunovant Stops IMVT-1402 Development in Cutaneous Lupus After Trial Miss
  Wed, Sep 23, 2026 12:12 PM
• Roivant Announces Topline Results from Proof-of-Concept Study of IMVT-1402 in Cutaneous Lupus Erythematosus
  Wed, Sep 23, 2026 11:00 AM
• Immunovant Ends Autoimmune Skin Disorder Program
  Wed, Sep 23, 2026 9:03 AM
• Roivant And Immunovant Say Topline Results From Period 1 Of Proof-of-concept Trial of IMVT-1402 (Imeroprubart) For Cutaneous Lupus Erythematosus Did Not Achieve Statistical Significance On The Primary Endpoint
  Wed, Sep 23, 2026 7:05 AM
• Roivant Sciences Ltd. (ROIV) Presents at Bank of America Global Healthcare Conference 2026 Transcript
  Tue, Sep 22, 2026 2:29 PM
• Roivant (ROIV): $9 Billion Sales Potential Faces a Commercialization Test
  Tue, Sep 22, 2026 10:27 AM
• What Is Roivant Sciences (ROIV) Signaling With Its Positive PH ILD Trial Data?
  Fri, Sep 18, 2026 11:15 AM
• This Paymentus Holdings Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
  Thu, Sep 17, 2026 7:51 AM
• Stifel Initiates Coverage On Roivant Sciences with Buy Rating, Announces Price Target of $51
  Thu, Sep 17, 2026 6:24 AM

Financial data not available